Company intelligence / Profile preview

Ancilia Biosciences

New York City, New York, United Statesanciliabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Proof-of-concept achieved for CRISPR-engineered live biotherapeutic immune to predatory viruses; preclinical data supports advancement toward IND filing for BV. NIH grant supports expansion into GI disease. No clinical results yet as programs are preclinical.[7][8]

Therapeutic areas: ImmunologyWomen's HealthGastroenterologyInfectious Diseases
Modalities: Live biotherapeutics (engineered bacteria)Microbial products with CRISPR-based viral immunity[1][3][5]
Industry: Biotech

Partnerships

ARPA-H Sprint for Women’s Health programNIH Small Business Technology Transfer grantInvestors include Safar Partners, Metaplanet, Psymed Ventures, Zubi Capital, Spacecadet Ventures.[3][4][8]

Beyond the preview

Go deeper on Ancilia Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ancilia Biosciences.

Explore the full profile